Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review

por Mearns, Elizabeth S, Bell, Jill A, Galaznik, Aaron, Puglielli, Stefanie M, Cichewicz, Allie B, Boulanger, Talia, Garcia-Ribas, Ignacio
Publicado 2018

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

por Kuboki, Yasutoshi, Shimizu, Toshio, Yonemori, Kan, Kojima, Takashi, Kondo, Shunsuke, Koganemaru, Shigehiro, Iwasa, Satoru, Harano, Kenichi, Koyama, Takafumi, Lu, Vickie, Zhou, Xiaofei, Niu, Huifeng, Yanai, Tomoko, Garcia-Ribas, Ignacio, Doi, Toshihiko, Yamamoto, Noboru
Publicado 2022